Ibuprofen abuse potential should prevent monograph status -- McKenna & Cuneo.
This article was originally published in The Tan Sheet
Executive Summary
IBUPROFEN ADVERSE EVENT REPORTING, SAFETY/EFFICACY RECOGNITION NEEDED, and therefore the drug should not be included in FDA's analgesic, antipyretic and antirheumatic drug products tentative final monograph, McKenna & Cuneo asserts in April 22 comments to the agency. The D.C. law firm opposes Whitehall-Robins Healthcare's citizen petition asking that ibuprofen (200 mg), which Whitehall sells as Advil, be added to the monograph as a single analgesic-antipyretic active ingredient. The American Home Products division filed the petition Nov. 28, citing the drug's 13-year marketing history and noting that monograph inclusion would "simplify the administrative burden" on both companies and FDA ("The Tan Sheet" Dec. 8, 1997, p. 4).
You may also be interested in...
Ibuprofen Detailed Renal, GI Warnings Required For Monograph Inclusion
Clinical study data and adverse event reports support inclusion of a warning on OTC ibuprofen labeling to alert consumers at risk for developing acute renal failure to consult a doctor, FDA says
Ibuprofen Detailed Renal, GI Warnings Required For Monograph Inclusion
Clinical study data and adverse event reports support inclusion of a warning on OTC ibuprofen labeling to alert consumers at risk for developing acute renal failure to consult a doctor, FDA says
Ibuprofen Detailed Renal, GI Warnings Required For Monograph Inclusion
Clinical study data and adverse event reports support inclusion of a warning on OTC ibuprofen labeling to alert consumers at risk for developing acute renal failure to consult a doctor, FDA says